VAMAS6
MCID: VTL009
MIFTS: 42

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (VAMAS6)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

MalaCards integrated aliases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Name: Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 57 13
Generalized Vitiligo 72 70
Vitiligo 72 70
Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 70
Vamas6 57
Vtlg 72

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
? epistatically interacting multiple autosomal recessive


HPO:

31
vitiligo-associated multiple autoimmune disease susceptibility 6:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM® 57 193200
MeSH 44 D014820
UMLS 70 C0042900 C1304470 C1847835

Summaries for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

UniProtKB/Swiss-Prot : 72 Vitiligo: A pigmentary disorder of the skin and mucous membranes. It is characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. Vitiligo is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases.

MalaCards based summary : Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6, also known as generalized vitiligo, is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and spastic paraplegia 23, autosomal recessive, and has symptoms including pruritus and exanthema. An important gene associated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22). The drugs mometasone furoate and Fluticasone have been mentioned in the context of this disorder. Affiliated tissues include skin, thyroid and t cells, and related phenotypes are vitiligo and nevus

More information from OMIM: 193200

Related Diseases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases in the Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 family:

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 638)
# Related Disease Score Top Affiliating Genes
1 vitiligo-associated multiple autoimmune disease susceptibility 1 12.0
2 spastic paraplegia 23, autosomal recessive 11.5
3 deafness, congenital, with vitiligo and achalasia 11.5
4 autoimmune disease 1 11.4
5 alopecia areata 11.3
6 alopecia universalis onychodystrophy vitiligo 11.2
7 alezzandrini syndrome 11.1
8 autoimmune disease 2 11.1
9 autoimmune disease 3 11.1
10 autoimmune disease 4 11.1
11 schrander-stumpel theunissen hulsmans syndrome 11.1
12 vogt-koyanagi-harada disease 11.0
13 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 11.0
14 autoimmune polyglandular syndrome type 3 11.0
15 stiff-person syndrome 11.0
16 familial cold autoinflammatory syndrome 3 11.0
17 halo nevus 10.9
18 vitiligo, progressive, with mental retardation and urethral duplication 10.9
19 hereditary spastic paraplegia 23 10.9
20 hemifacial atrophy, progressive 10.9
21 autoimmune atrophic gastritis 10.9
22 ermine phenotype 10.8
23 combined cellular and humoral immune defects with granulomas 10.8
24 nijmegen breakage syndrome 10.8
25 lelis syndrome 10.8
26 t-cell receptor-alpha/beta deficiency 10.8
27 hypopigmentation of eyelid 10.8
28 gemignani syndrome 10.8
29 pigmentation anomaly of the skin 10.8
30 skin disease 10.8
31 autoimmune disease 10.7
32 alopecia 10.7
33 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
34 melanoma 10.7
35 psoriasis 10.6
36 pustulosis of palm and sole 10.6
37 thyroiditis 10.6
38 hypothyroidism 10.6
39 dowling-degos disease 1 10.5
40 dermatitis 10.5
41 skin carcinoma 10.5
42 dermatitis, atopic 10.4
43 hashimoto thyroiditis 10.4
44 lichen planus 10.4
45 halo nevi 10.4
46 thyroid gland disease 10.3
47 pernicious anemia 10.3
48 graves' disease 10.3
49 uveitis 10.3
50 systemic scleroderma 10.3

Graphical network of the top 20 diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:



Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Symptoms & Phenotypes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Human phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

31
# Description HPO Frequency HPO Source Accession
1 vitiligo 31 HP:0001045
2 nevus 31 HP:0003764

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Skin:
vitiligo
halo nevi

Misc:
onset after birth
no predilection for ventral skin

Clinical features from OMIM®:

193200 (Updated 05-Apr-2021)

UMLS symptoms related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:


pruritus; exanthema

Drugs & Therapeutics for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Drugs for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
2
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
3
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
4
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
5
Dinoprost tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
6
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078
7
Travoprost Approved Phase 4 157283-68-6 5282226
8
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 444795 5538
9 Dermatologic Agents Phase 4
10 Anti-Allergic Agents Phase 4
11 Anti-Asthmatic Agents Phase 4
12 Respiratory System Agents Phase 4
13 Bronchodilator Agents Phase 4
14 abobotulinumtoxinA Phase 4
15 Neurotransmitter Agents Phase 4
16 Cholinergic Agents Phase 4
17 Botulinum Toxins Phase 4
18 Botulinum Toxins, Type A Phase 4
19 Furocoumarins Phase 4
20
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
21
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 6473866 445643 439492
22
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
23 Janus Kinase Inhibitors Phase 3
24 Immunosuppressive Agents Phase 2, Phase 3
25 Immunologic Factors Phase 2, Phase 3
26 Calcineurin Inhibitors Phase 2, Phase 3
27 Triamcinolone hexacetonide Phase 2, Phase 3
28 Triamcinolone diacetate Phase 2, Phase 3
29 Hormone Antagonists Phase 2, Phase 3
30 glucocorticoids Phase 2, Phase 3
31 triamcinolone acetonide Phase 2, Phase 3
32 Hormones Phase 2, Phase 3
33
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
34
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
35
Simvastatin Approved Phase 2 79902-63-9 54454
36
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 6447131 17753757
37
Etanercept Approved, Investigational Phase 2 185243-69-0
38
Afamelanotide Approved, Investigational Phase 2 75921-69-6
39
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
40
Atorvastatin Approved Phase 1, Phase 2 134523-00-5 60823
41
Tofacitinib Approved, Investigational Phase 2 477600-75-2
42
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
43
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
45 Hydrocortisone-17-butyrate Phase 1, Phase 2
46 Hydrocortisone hemisuccinate Phase 1, Phase 2
47 Hydrocortisone 17-butyrate 21-propionate Phase 1, Phase 2
48 Anticholesteremic Agents Phase 2
49 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
50 Lipid Regulating Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 154)
# Name Status NCT ID Phase Drugs
1 Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) Unknown status NCT01082393 Phase 4 topical tacrolimus treatment;topical pimecrolimus treatment;local mometasone furoate treatment;cold cream
2 Autologous Punch Grafting in Vitiligo Patients: the Effect of Punchdepth and Punchsize Unknown status NCT01377077 Phase 4
3 Comparison the Efficacy and Safety of 0.1% Tacrolimus Ointment With 0.1% Mometasone Furoate Cream in the Treatment of Adult Vitiligo: A Single Blinded Pilot Study Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
4 Bimatoprost 0.03% Solution, NB-UVB and Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo Unknown status NCT03487042 Phase 4 Bimatoprost 0.03% ophthalmic solution
5 Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
6 Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo Unknown status NCT03199664 Phase 4
7 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Pilot Study Unknown status NCT01640678 Phase 4
8 Botulinum Toxin Treatment for Localized Vitiligo Completed NCT01051687 Phase 4 Botulinum toxin A
9 Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo Completed NCT01732965 Phase 4
10 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Study on the Recipient Site Preparation Completed NCT02458417 Phase 4
11 Efficacy and Safety of Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive Vitiligo Recruiting NCT04775979 Phase 4 diphenylcyclopropenone (DPCP)
12 Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation Active, not recruiting NCT04811326 Phase 4 Latanoprost
13 Safety And Efficacy Of Topical Prostaglandin F2α Analogs In Combination With Fractional CO2 Laser And 308 Excimer Light In Treatment Of Vitiligo Not yet recruiting NCT04577027 Phase 4 Topical travoprost 0.004% solution
14 Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study Withdrawn NCT01202513 Phase 4 Bimatoprost 0.03% topical ophthalmic solution
15 Effectiveness of Microneedling and Topical Latanoprost in Treatment of Acrofacial Vitiligo Unknown status NCT03611348 Phase 2, Phase 3 Latanoprost
16 Efficacy of Tacrolimus Ointment 0.1% Versus Placebo in Adults With Facial Non-segmental Vitiligo: a Randomized Double-blind Controlled Study Unknown status NCT02466997 Phase 3 tacrolimus;Placebo
17 Continuative vs Sequential Phototherapy in Non-segmental Vitiligo Patients Unknown status NCT00525395 Phase 3
18 Safety and Efficacy of Melanocyte-keratinocyte Transplantation in the Treatment of Vitiligo Completed NCT00830713 Phase 3
19 Treatment of Vitiligo With Narrowband UVB (TL01) Combined With Tacrolimus (0.1%) Versus Placebo Ointment, a Randomized Right/Left Double Blind Comparative Study Completed NCT00807690 Phase 3 Tacrolimus ointment
20 Efficacy and Tolerance of Transplantation of Harvested Epidermal Cells and Narrow-Band UVB in Vitiligo Completed NCT01629979 Phase 2, Phase 3
21 Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo Completed NCT01087216 Phase 2, Phase 3 Bras B : The group control
22 Comparative Study of 308nm Excimer Lamp and 308nm Excimer Laser in the Treatment of Vitiligo Completed NCT00696358 Phase 3
23 Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin Completed NCT00631865 Phase 3
24 A Multicenter Double-blind Placebo-controlled Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism) Completed NCT02156427 Phase 3
25 A Randomized, Double-blind, Vehicle-Controlled, Phase II/Ⅲ Seamless Adaptive Clinical Trail to Evaluate the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo Recruiting NCT04774809 Phase 2, Phase 3 Low Dose SHR0302 Ointment BID;High Dose SHR0302 Ointment BID
26 A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo Recruiting NCT04530344 Phase 3 ruxolitinib;Vehicle
27 Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo Active, not recruiting NCT04057573 Phase 3 Ruxolitinib cream;Vehicle
28 Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo Active, not recruiting NCT04052425 Phase 3 Ruxolitinib cream;Vehicle
29 Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Terminated NCT02191748 Phase 2, Phase 3 Triamcinolone
30 Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control, Randomized and Double Blind Study Terminated NCT01841008 Phase 2, Phase 3 Protopic;Placebo : Diprobase
31 Comparative Study of the Use of Trypsin Versus Dispase in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo Withdrawn NCT01822379 Phase 2, Phase 3
32 Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo Withdrawn NCT01419964 Phase 3 Group 01;Group 02
33 UVA 1 Phototherapy for Vitiligo Unknown status NCT01787695 Phase 2
34 Treatment and Complication of Bath PUVA in Vitiligo Unknown status NCT00380471 Phase 2
35 Efficacy of Red Light in Vitiligo: A Prospective, Single-Blind Randomized Controlled Trial Unknown status NCT01787708 Phase 2
36 Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand: A Prospective Randomized, Single-blinded Controlled Clinical Trial Unknown status NCT01792245 Phase 2
37 Efficacy and Safety of Intralesional Triamcinolone Acetonide in Vitiligo: A Prospective, Double-Blind Randomized Controlled Trial Unknown status NCT01766609 Phase 2 Triamcinolone Acetonide
38 Effectivness of Topical Tacrolimus 0.03% Monotherapy in Patients With Vitiligo: Arandomized Controlled Trial Unknown status NCT03358082 Phase 1, Phase 2 Tacrolimus 0.03% Ointment;Hydrocortisone Acetate 1% Ointment
39 A Phase-II, Randomized, Placebo-controlled Trial of Simvastatin in Generalized Vitiligo Completed NCT01517893 Phase 2 Simvastatin;Placebo
40 Pilot, Investigator-Initiated, Proof-of-Concept, Study of the Efficacy and Safety of Etanercept (Enbrel) in Adults With Vitiligo Completed NCT00134368 Phase 2 Etanercept
41 A Phase II Randomised Pilot Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Completed NCT01382589 Phase 2 Afamelanotide
42 Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO RAPID VITILIGO Completed NCT03036995 Phase 2 Apremilast
43 A Two-Arm, Randomized, Double-Blind, Phase IIb Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants Plus Narrow-Band Ultraviolet B (NB-UVB) Light Source in the Treatment of Nonsegmental Vitiligo AND A Single-Arm, Open Label, Phase IIb Study to Evaluate the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants Plus Narrow-Band Ultraviolet B (NB-UVB) Light Source in the Treatment of Nonsegmental Vitiligo Completed NCT04525157 Phase 2 Afamelanotide;Placebo
44 Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo Completed NCT01511965 Phase 1, Phase 2
45 Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris Completed NCT00372307 Phase 2 Application of pimecrolimus
46 Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo Completed NCT02809976 Phase 2 Ruxolitinib 1.5% Phosphate Cream
47 A Split Body Study of the Effects of Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Completed NCT03123016 Phase 2 Apremilast
48 A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO Completed NCT03715829 Phase 2 PF-06651600;PF-06651600;PF-06651600;PF-06651600;PF-06651600;placebo;PF06700841
49 The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo (EVRAAS) Completed NCT03247400 Phase 1, Phase 2 1% simvastatin-acid sodium salt ointment;1% atorvastatin calcium salt ointment
50 An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo Completed NCT03468855 Phase 2 ATI-50002 topical solution

Search NIH Clinical Center for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Methoxsalen
monobenzone
Trioxsalen

Genetic Tests for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Anatomical Context for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

MalaCards organs/tissues related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

40
Skin, Thyroid, T Cells, Liver, Lung, Bone, Breast

Publications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Articles related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

(show top 50) (show all 7276)
# Title Authors PMID Year
1
Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. 61 57
20526339 2010
2
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. 57 61
20410501 2010
3
Vitiligo: complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA. 61 57
11941482 2002
4
Immune privilege of skin stem cells: What do we know and what can we learn? 61
33103270 2021
5
Gaining Insight into Vitiligo Genetics through the Lens of a Large Epidemiologic Study. 61
33752810 2021
6
Needling as a Method to Highlight the Margins of a Vitiligo Patch During Melanocyte-Keratinocyte Transplantation. 61
32205754 2021
7
Familial Risk of Vitiligo among First-Degree Relatives and Spouses: A Population-Based Cohort Study in Korea. 61
32888956 2021
8
New Pigmentation After Medical Treatment Suggests Increased Efficacy of Dermabrasion and Noncultured Epidermal Cell Suspension Techniques in Stable Vitiligo. 61
33038103 2021
9
The attentive focus on T cell-mediated autoimmune pathogenesis of psoriasis, lichen planus and vitiligo. 61
33190330 2021
10
Efficacy of 308-nm excimer laser treatment for refractory vitiligo: a case series of treatment based on the minimal blistering dose. 61
33232541 2021
11
Novel immunological and genetic factors associated with vitiligo: A review. 61
33717255 2021
12
Tumor Necrosis Factor-alpha affects melanocyte survival and melanin synthesis via multiple pathways in vitiligo. 61
33517195 2021
13
Quality of life, emotion dysregulation, attention deficit and psychiatric comorbidity in children and adolescents with vitiligo. 61
32064670 2021
14
Posttraumatic Stress Disorder and the Associated Risk of Autoimmune Skin Diseases: A Nationwide Population-Based Cohort Study. 61
33587564 2021
15
Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. 61
33608949 2021
16
Skin pigmentation and its control: From ultraviolet radiation to stem cells. 61
33320376 2021
17
Differences in phototherapy among skin diseases and genders in real-life conditions - a retrospective analysis of the cumulative doses, numbers of sessions, side effects and costs in 561 patients. 61
33793982 2021
18
Engineered antigen-specific regulatory T cells for autoimmune skin conditions. 61
33476816 2021
19
Comparison of efficacy and safety of traditional Chinese patent medicine in the treatment of vitiligo in children or adults: A protocol for systematic review and network meta-analysis. 61
33725959 2021
20
Vitiligo masquerading as annular erythema in a young woman with low-grade skin phototype. 61
33660276 2021
21
Increased risk of subclinical atherosclerosis and metabolic syndrome in patients with vitiligo: a real association or a coincidence? 61
33496053 2021
22
Analysis of Matched Skin and Gut Microbiome of Vitiligo Patients Reveals Deep skin Dysbiosis: Link with Mitochondrial and Immune Changes. 61
33771527 2021
23
Vitiligo: A focus on pathogenesis and its therapeutic implications. 61
33404102 2021
24
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. 61
33683075 2021
25
Factors associated with perceived-stress in patients of the vitiligo ComPaRe e-cohort. 61
33684495 2021
26
Oral mini-pulse therapy in vitiligo: a systematic review. 61
33729554 2021
27
The unfolded protein and integrated stress response in melanoma and vitiligo. 61
33215847 2021
28
The fate of melanocyte: Mechanisms of cell death in vitiligo. 61
33346939 2021
29
Clinical aspects of vitiligo. 61
33756039 2021
30
An update on Vitiligo pathogenesis. 61
33278065 2021
31
Vitiligo in Asian children: A retrospective review. 61
33660841 2021
32
Effect of platelet-rich plasma on the outcome of mini-punch grafting procedure in localized stable vitiligo: Clinical evaluation and relation to lesional basic fibroblast growth factor. 61
33403743 2021
33
Effectiveness of dermabrasion plus 5-fluorouracil vs suction blister in treating vitiligo: A comparative study. 61
33403790 2021
34
Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib. 61
33667323 2021
35
Proposing a novel unsupervised stack ensemble of deep and conventional image segmentation (SEDCIS) method for localizing vitiligo lesions in skin images. 61
32662570 2021
36
Hypopigmented Mycosis Fungoides Mimicking Vitiligo. 61
33156019 2021
37
Reply to "Elastin fiber but not collagen fiber is decreased dramatically in the dermis of vitiligo patients": possible mechanisms of decreased elastin fibers. 61
33410498 2021
38
Vitiligo: an update on systemic treatments. 61
33350506 2021
39
Residual Pigment Islands Treated With 88% Phenol Peeling in a Woman With Universal Vitiligo. 61
32931752 2021
40
DEFB1 gene polymorphisms modify vitiligo extent and response to NB-UVB phototherapy. 61
33647170 2021
41
Serum TWEAK: A cutoff between segmental and nonsegmental vitiligo. 61
32808442 2021
42
A protective role for autophagy in vitiligo. 61
33767135 2021
43
NB-UVB plus oral Polypodium leucotomos extract display higher efficacy than NB-UVB alone in patients with vitiligo. 61
33433041 2021
44
Comparative efficacy between localized 308-nm excimer light and targeted 311-nm narrowband ultraviolet B phototherapy in vitiligo: A randomized, single-blind comparison study. 61
33047405 2021
45
Efficacy of the combined excimer light and topical calcipotriol for acral vitiligo: A randomized double-blind comparative study. 61
33595885 2021
46
LRP1/CD91 is highly expressed in monocytes from patients with vitiligo - even after repigmentation. 61
33249636 2021
47
Ocular and auditory abnormalities in vitiligo patients: A case- control study. 61
33763919 2021
48
A comparative study of combined microneedling and narrowband ultraviolet B phototherapy versus their combination with topical latanoprost in the treatment of vitiligo. 61
33497514 2021
49
Integrated analysis of miRNA-mRNA networks reveals a strong anti-skin cancer signature in vitiligo epidermis. 61
33682215 2021
50
Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. 61
33711672 2021

Variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

ClinVar genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 KIF1B NM_015074.3(KIF1B):c.4387C>T (p.Arg1463Cys) SNV Uncertain significance 374063 rs757850683 GRCh37: 1:10425479-10425479
GRCh38: 1:10365421-10365421

UniProtKB/Swiss-Prot genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

72
# Symbol AA change Variation ID SNP ID
1 PTPN22 p.Arg620Trp VAR_022605 rs2476601

Expression for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Search GEO for disease gene expression data for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6.

Pathways for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

GO Terms for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Sources for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....